1. K. H. Tkaczuk, N. S. Tait, O. Ioffe, M. Tan, M. Mohiuddin, S. Chumsri, D. A. VanEcho, M. J. Sutula, S. Lesko, S. Deamond, P. Ts’o; Drug Response Indicator Test (DRIT) as a predictive test for treatment outcomes in advanced breast cancer patients (ABC). Clin Oncol 27:15s, 2009 (suppl; abstr 1119). University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics, LLC, Baltimore, MD.

2. N. B. Pandya, K. R. Tkaczuk, N. Tait, O. Ioffe, M. Tan, D. A. Van Echo, M. J. Sutula, S. A. Lesko, S. F. Deamond, P. O. Ts’o; A predictive test for therapeutic treatment outcomes of advanced gastrointestinal cancer patients (AGC). J Clin Oncol 27, 2009 (suppl; abstr e15079). University of Maryland Greenebaum Cancer Center, Baltimore, MD; HarborView Cancer Center, Baltimore, MD; CCC Diagnostics, LLC, Baltimore, MD.

3. K Tkaczuk, N.S. Tait, O. Ioffe, W. Rodgers, M. Tan, S.A. Lesko, Z.P. Lum, S.F. Deamond,E. Shan, D.B. Zhou, , J.R. Daniel, D.A.Van Echo, P.O.P. Ts’o. University of Maryland Greenebaum Center, Baltimore, CCC Diagnostics, LLC, Baltimore, Maryland. A Retrospective Study of the Drug Response Indicator Test (DRIT) as a Predictive Test for Therapeutic Outcomes of Advanced Breast Cancer Patients (ABC), Presented at the 31st Annual San Antonio Breast Cancer Symposium, Texas, December 10-14, 2008.

4. Paul O.P Ts’o, Stephen Lesko, ZP Lum, Scott Deamond, Enzhi Shan, David Zhou, John Daniel, David Van Echo, Katherine H Rak Tkaczuk, Nancy Tait, Olga Ioffe, Naimish Pandya, William Rodgers , Ming Tan. Drug response indicator test (DRIT) – A predictive diagnostic laboratory service for anticancer treatment of individual patients. Submitted to AACR: Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine, September 22-25, 2008, Philadelphia, PA.;CCC Diagnostics, LLC, Baltimore, MD; University of Maryland Greenebaum Cancer Center, Baltimore, MD.

5. PO Ts’o, SA Lesko, ZP Lum, S Deamond, E Shan, D Zhou, J Daniel, D Van Echo, K Tkaczuk, NS Tait, F Feldman, O Ioffe, W Rodgers M Tan. CCC Diagnostics, LLC, Baltimore, MD, University of Maryland Greenebaum Cancer Center, Baltimore, MD. Drug Response Indicator Test (DRIT) – a diagnostic laboratory service that measures DRI (biomarker) expression levels in tumors for predicting treatment outcome of anticancer chemotherapy for individual patients. Presented at Biomarker World Congress 2008, May 19-21, 2008, Philadelphia, PA.; CCC Diagnostics, LLC, Baltimore, MD.; University of Maryland Greenebaum Cancer Center, Baltimore, MD.

6. Katherine H Rak Tkaczuk, Nancy S Tait, William H Rodgers , Ming Tan, Olga Ioffe, Steve A Lesko, Scott Deamond, Zhao-Ping Lum, Paul O Ts’o. Retrospective Study in Breast Cancer Patients (BC) correlating the clinical responses to anticancer drugs with the level of expression of the drug response indicators (DRI) in the tumor tissue. Presented at 19th International Congress on Anti Cancer Treatment, February 5-8, 2008, Paris, France.; University of Maryland Greenebaum Cancer Center Program of Oncology; CCC Diagnostics LLC, Baltimore, MD.

7. KHR Tkaczuk, NS Tait, WH Rodgers, M Tan, O Ioffe, SA Lesko, S Deamond, ZP Lum, POP Ts’o.Retrospective clinical correlation study on the patients’ responses to anticancer drugs with the expression level of drug response indicators (DRI) measured in patient’s archival tumor tissue. Presented at 30th Annual San Antonio Breast Cancer Symposium, December 13 – 16, 2007, at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

8. Ts’o, POP, Lesko, SA, Lum, ZP, Deamond, S, Shan, E, Zhou, D, Daniel, JR, Van Echo, D, Tkaczuk, K, Tait, NS, Feldman, F, Edelman, MJ, Suntharalingam, M, Tan, M, Rodgers, W. Drug Response Indicator Test (DRIT) for personalized anticancer chemotherapy for late stage breast cancer (BC) and non-small cell lung cancer (NSCLC) patients.The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, October 22-26, 2007, San Francisco, CA. CCC Diagnostics, LLC, Baltimore, MD, University of Maryland Greenebaum Cancer Center, Baltimore, MD.

9. Tkaczuk , KHR, Tait, NS, Rodgers, WH, Tan,M, Ioffe, O, Lesko, SA, Deamond,S, Lum, ZP, Ts’o, POP. Clinical Studies Correlating Patients’ Responses To Anticancer Drugs With The Level Of Expression Of Drug Response Indicators (Dri) Measured In The Patient’s Tumor Tissue.The 4th Congress of the World Society for Breast Health Meeting, Tianjin, China, October 18-21, 2007. University of Maryland Departments of Oncology; Pathology; Biostatistics; CCC Diagnostics LLC, Baltimore, MD.

10. Ts’o, POP, Lesko, SA, Lum, ZP, Deamond, S, Shan, E, Zhou, D, Daniel, JR, Van Echo, D, Tkaczuk, K, Tait, NS, Tan, M, Ioffe, O, Rodgers, W. Drug Response Indicator Test (DRIT) for personalized anticancer chemotherapy for stage IV breast cancer (BC) patients. AACR Breast Cancer Conference, October 17-20, 2007, San Diego, CA. Poster. CCC Diagnostics, LLC, Baltimore, MD; University of Maryland Greenebaum Cancer Center, Baltimore, MD.

11. Edelman, MJ, Kwong, K, Suntharalingam, M, Tan, M, Rodgers, W, Lesko, S, Ts’o,POP.ERCC1 and Beta Tubulin III (BTUB) Isoform Expression by Immunofluorescence (IF) May Correlate with Survival after Combined Modality Therapy (CMT) for Stage III NSCLC.International Association for the Study of Lung Cancer, 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007.

12. Tkaczuk, KA, Van Echo, DA, Tait, N, Feldman, F, Lum, ZP, Lesko, S, Ts’o, POP;University of Maryland Greenebaum Cancer Center, Baltimore, MD/CCC Diagnostics, Baltimore, MD. Circulating Cancer Cells in Breast Cancer Patients. 2005 ASCO Meeting.

13. Ts’o, POP, Lesko, SA, Lum, ZP, Deamond, SF, Shan, E, Zhou, DB, Daniel JR. Personalized anticancer chemotherapy based on the measurement of drug response indicators (DRI) expressed by cancer cells. AACC 37th Oakridge Meeting, Abstract # 32, April 2005, Baltimore, MD.

14. Edelman, MJ, Bisaccia, S, Smith, R, Lesko, SA, Lum, ZP, Ts’o, POP; University of Maryland Greenebaum Cancer Center, Baltimore, MD/CCC Diagnostics LLC, Baltimore, MD. Circulating cancer cells (CCC) in non-small cell lung cancer (NSCLC): incidence and preliminary observations on prognostic significance and potential for individualized therapy. 2005 ASCO Meeting.

15. Ts’o, POP, Lesko, SA, Lum, ZP , Deamond, SF, Shan, E, Zhou, DB, Daniel, JR, CCC Diagnostics, LLC, Baltimore, MD. Drug Response Indicators in Cancer Cells Provide the Basis of Personalized Anticancer Chemotherapy. 7th Annual NIH SBIR/STTR Conference July 2005.

16. Ts’o, POP, Lesko, SA, Lum, ZP, Deamond, SF, Shan, E, Zhou, DB, Daniel, JR, Tkaczuk, KH, Tait, NS, Feldman, F, Van Echo DA, CCC Diagnostics, LLC, University of Maryland Greenebaum Cancer Center, HarborView Cancer Center, Baltimore, Maryland. Drug response indicators in cancer cells provide the bases of personalized anticancer chemotherapy (PAC) for breast cancer (BC). AACR Conference, September 2005, La Jolla, California.